AstraZeneca PLC
AZN | LSE
Overview
Corporate Details
- ISIN(s):
- GB0009895292 (+925 more)
- LEI:
- PY6ZZQWO2IZFZC3IOL08
- Country:
- United Kingdom
- Address:
- 1 FRANCIS CRICK AVENUE, CB2 0AA CAMBRIDGE
- Website:
- https://www.astrazeneca.com/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
We are a global, science-led, patient-focused pharmaceutical company. We are tireless in seeking to realise the potential of what science can do. We are focused on creating genuinely innovative medicines and improving access to them. In this way, we deliver the greatest benefit to patients, healthcare systems and societies globally. We have three priorities designed to deliver our growth through innovation strategy. Oncology We are leading a revolution in oncology to redefine cancer care. Our ambition is to provide cures for cancer in every form. BioPharmaceuticals We want to change the lives of billions of people living with chronic diseases for the better. Rare Disease Our mission is to transform the lives of people affected by rare diseases and devastating conditions.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-06 08:00 |
Regulatory News Service
Fixed-duration Calquence approved in EU for 1L CLL
|
English | 21.9 KB | |
| 2025-06-02 16:05 |
Share Issue/Capital Change
Block listing Interim Review
|
English | 15.2 KB | |
| 2025-06-02 16:00 |
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
|
English | 8.9 KB | |
| 2025-05-27 08:00 |
Earnings Release
Imfinzi recommended in EU for bladder cancer
|
English | 27.0 KB | |
| 2025-05-23 11:00 |
Directors' Dealings
Director/PDMR Shareholding
|
English | 22.8 KB | |
| 2025-05-07 08:30 |
Regulatory News Service
Enhertu improved pCR in early-stage breast cancer
|
English | 31.2 KB | |
| 2025-04-29 08:10 |
Regulatory News Service
Fixed-duration Calquence recommended in EU for CLL
|
English | 21.3 KB | |
| 2025-04-29 08:05 |
Regulatory News Service
Update on CAPItello-280 Phase III trial
|
English | 19.3 KB | |
| 2025-04-22 08:00 |
Regulatory News Service
Enhertu combination improved PFS in 1L HER2+ mBC
|
English | 33.1 KB | |
| 2025-04-11 18:17 |
AGM Report
Special Business Approved at AGM
|
English | 131.0 KB | |
| 2025-03-17 08:10 |
Regulatory News Service
Eneboparatide Phase III trial met primary endpoint
|
English | 16.9 KB | |
| 2025-03-17 08:05 |
Regulatory News Service
Imfinzi approved in EU for limited-stage SCLC
|
English | 29.6 KB | |
| 2025-03-17 08:00 |
Regulatory News Service
AstraZeneca to acquire EsoBiotec
|
English | 13.5 KB | |
| 2025-03-12 19:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 26.3 KB | |
| 2025-03-12 09:43 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 9.0 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-03-06 | Pascal Soriot | Other | Other | 8,853 | N/A |
| 2023-03-04 | Pascal Soriot | Other | Other | 100,256 | 10,848,701.76 EUR |
| 2023-03-04 | Aradhana Sarin | Other | Other | 45,449 | 4,918,036.29 EUR |
| 2023-02-09 | Pascal Soriot | Other | Other | 15,187 | N/A |
| 2022-12-23 | Pascal Soriot | Other | Other | 163,838 | N/A |
| 2022-03-24 | Pascal Soriot | Other | Other | 129,784 | N/A |
| 2022-03-08 | Pascal Soriot | Other | Other | 9,930 | N/A |
| 2022-02-10 | Pascal Soriot | Other | Other | 24,124 | N/A |
| 2021-09-30 | Pascal Soriot | Other | Other | 231,922 | N/A |
| 2021-08-13 | Aradhana Sarin | Other | Other | 31,690 | 2,601,432.10 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Antibiotice S.A. | Romania | ATB | |
|
Aran Research & Development (1982) Ltd. | Israel | ARAN | |
|
Asarina Pharma AB | Sweden | ASAP |